Aditya Bardia

Has grant

UCLA Health
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Precision Antibody Drug Conjugates to target Metastatic Breast Cancer

Open Date: 2023-10-01

Close Date: 2024-09-30

Articles (49)

Differences in elacestrant efficacy in patients with polyclonal versus single ESR1 -mutant tumors. Among this cohort of patients with a baseline ESR1 mutation detected within 6 months of elacestrant start, clinical outcomes in patients with two, three, or four or more detectable ESR1 alterations were compared with patients with one ESR1 mutation. A depicts the TTNT on elacestrant, B depicts the TTD, and C depicts the OS comparing those with two ESR1 mutations in red, three in green, and four or more in brown against patients with a single ESR1 mutation in blue. The adjusted HR and corresponding 95% CI are displayed. Vertical hash marks denote a censored patient event. ESR1 alt denotes ESR1 alteration. alt, alteration; CL, confidence limit; pts, patients.

Year:

2026

Clinical outcomes in patients treated with elacestrant. A depicts the TTNT since elacestrant initiation in this cohort of patients with MBC and ESR1 mutation detected within 6 months prior to therapy start. B displays the TTD in this cohort, and C displays the OS. Vertical hash marks denote a censored patient event. CL, confidence limit.

Year:

2026

Patient outcomes on elacestrant by prior lines of therapy. TTNT ( A ), TTD ( B ), and OS ( C ) on elacestrant are depicted comparing differences in outcomes by the number of prior lines of metastatic therapy. Patients who received elacestrant after one or fewer prior lines are displayed in blue, after two prior lines are displayed in red, and after three or more prior lines are displayed in green. Adjusted HR and corresponding 95% CI are displayed comparing patients with two prior lines and three or more prior lines with those with one or fewer prior lines of metastatic therapy before elacestrant initiation. Vertical hash marks denote a censored patient event. CL, confidence limit; pts, patients.

Year:

2026

Purpose: ESR1 mutations mediate resistance to antiestrogen therapy in hormone receptor–positive metastatic breast cancer (MBC). Elacestrant, an oral selective estrogen receptor degrader, improves progression-free survival over standard endocrine therapy in ESR1 -mutant MBC. We assessed real-world elacestrant use and clinical–genomic factors associated with outcomes. Experimental Design: This study used the GuardantINFORM database, linking >42,000 real-world breast cancer cases with sequencing and claims data. We included patients with activating ESR1 mutations detected Results: We identified 756 patients (76% with prior cyclin-dependent kinase-4/6 inhibitor and 38% with prior chemotherapy exposure), and 742 (98.2%) were evaluable for outcomes. The median TTNT was 6.4 months, and the time-to-treatment-discontinuation was 4.6 months. In those with ≤1 prior lines of metastatic therapy, the TTNT was 8.8 months, compared with 6.0 months in the third-line setting. Prior fulvestrant exposure trended toward shorter treatment duration (hazard ratio, 1.19; 95% confidence interval, 0.91–1.56). Higher ESR1 polyclonality (≥4 alterations; 11% of patients) correlated with a shorter TTNT of 5.2 months (hazard ratio, 1.44; 95% confidence interval, 1.01–2.06), but efficacy was consistent across ESR1 alleles (e.g., Y537S and D538G ). Disease with dual ESR1 and PI3K pathway mutations ( PIK3CA , AKT1 , and PTEN ) had a median TTNT of 5.2 months. Conclusions: In ESR1 -mutant MBC, elacestrant treatment durations support the routine use of elacestrant monotherapy in appropriately selected patients. For patients with concurrent ESR1 and PI3K pathway mutations, single-agent activity was comparable with outcomes observed in phase III studies. See related article by Rugo et al., p. 179

Year:

2026

PI3K pathway alterations are associated with differences in clinical outcomes on elacestrant. Patients with PI3K pathway–altered tumors were defined by the presence of an oncogenic PIK3CA , AKT1 , and/or PTEN alteration detected within 6 months prior to elacestrant exposure. Clinical outcomes in patients with PI3K pathway–altered disease (in red) were compared with those without a PI3K pathway alteration (in blue) via the TTNT (depicted in A ), TTD (depicted in B ), and OS (depicted in C ). The adjusted HR and corresponding 95% CI are displayed. Vertical hash marks denote a censored patient event CL, confidence limit.

Year:

2026

Elacestrant therapy duration and OS by prior fulvestrant exposure. Depicted are clinical outcomes on elacestrant therapy comparing patients with versus those without previous treatment with fulvestrant. Patients treated with fulvestrant before elacestrant are displayed in red, and those without prior fulvestrant are displayed in blue. A depicts the TTNT, B depicts the TTD, and C depicts the OS. The adjusted HR and corresponding 95% CI comparing the two groups are displayed. Vertical hash marks denote a censored patient event. CL, confidence limit.

Year:

2026

Purpose: Antibody–drug conjugates (ADC) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer. However, knowledge of ADC resistance mechanisms and potential impact on the sequential use of ADCs is limited. In this study, we report the incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in metastatic breast cancer. Experimental Design: Patients with metastatic breast cancer treated with ADCs with available posttreatment plasma-based genotyping were included. TOP1 mutation incidence, mutant allele frequency, and functional characterization were assessed, and incidence was compared with that in patients with metastatic breast cancer not receiving ADC treatment and in The Cancer Genome Atlas. Results: Plasma-based genotyping identified distinct TOP1 mutations (S57C, R364H, W401C, and G359E) in 12.9% of patients (4/31) at the time of disease progression on ADC, compared with 0.7% (3/420) in non–ADC-treated patients with metastatic breast cancer and 0.5% in The Cancer Genome Atlas. The appearance of mutations was associated with clinical cross-resistance, as median duration on the first ADC was 455 versus 52 days for the second ADC. The functional characterization of three novel TOP1-mutant proteins demonstrated that all exhibited reduced enzymatic activity, attenuated covalent DNA binding, and resistance to TOP1 inhibitor ADC payloads SN38 and deruxtecan. Conclusions: We describe the recurrent emergence of functionally altered, resistance-associated TOP1 mutations in vivo under selective pressure from ADCs and the potential impact on mediating cross-resistance to sequential ADCs. TOP1 mutation may represent a biomarker of resistance in this setting, and additional work is needed to optimize biomarkers and ADC payload design to improve outcomes for the sequential use of ADCs. See related commentary by Gwin and Hurvitz, p. 1824

Year:

2025

Background The surrogacy of overall response rate (ORR) or progression-free survival (PFS) for overall survival (OS) at the trial-level in randomized clinical trials (RCTs) testing antibody-drugs conjugates (ADC) has never been investigated. Methods RCTs testing ADCs in patients with advanced solid tumors and reporting data on OS and PFS and/or ORR were analyzed. The main objective was to assess the trial-level association between the surrogate endpoints (ORR or PFS) and the reference endpoint (OS), overall and in subgroups of trials defined by tumor type, number of previous lines of systemic treatments, and specific ADC features. Results Twenty-five RCTs, for a total of 26 treatment comparisons and 11 729 patients, were included in the analysis. In 21 comparisons the ADC was administered as monotherapy, and in 16 was tested in patients with breast cancer. The association between the hazard ratio for OS and relative risk of ORR was moderate: the R2 from a model adjusted by tumor type was 0.47 (95% CI = 0.11 to 0.83). The association between the hazard ratios for OS and PFS was strong: the R2 from the adjusted model was 0.79 (95% CI = 0.66 to 0.92). Cross-validation analyses showed similar results. Consistent results were obtained across all the subgroups analyzed, with the notable exception of the subgroup of trials testing ADCs for breast cancer, where the association between OS and ORR appeared strong (R2 = 0.77; 95% CI = 0.51 to 0.90). Conclusions In RCTs evaluating ADCs in advanced solid tumors, PFS serves as a robust surrogate endpoint for OS, offering greater reliability than ORR and adequately supporting accelerated approval of ADCs in future trials.

Year:

2025

Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules. Patients with stage I–III hormone receptor-positive (HR+)/HER2– breast cancer on adjuvant endocrine therapy (ET) were randomized to two ribociclib dosing schedules: 400 mg continuous vs 600 mg intermittent, with initiation in early (prior ET < 2 years) vs delayed (prior ET ≥ 2 years) setting. Primary objective was to evaluate safety and tolerability of continuous vs intermittent schedule. Primary endpoint was proportion of patients who discontinued ribociclib before completion of all 12 cycles (measured at 12 months). Recurrence free survival (RFS) and circulating tumor DNA (ctDNA) detection were also evaluated. 81 patients were enrolled. Only six serious adverse events occurred, with no significant difference between treatment arms and no subject deaths. Twenty-five patients (31%) discontinued ribociclib before completion of 12 months, with no significant difference between treatment arms. Ribociclib discontinuation was higher in early vs delayed initiation (36% vs 21%). At median follow-up of 20 months, two patients in the intermittent arm (600 mg; Arm 2) experienced disease recurrence (2-year RFS 97%, 95%CI 88–99%), vs none in the continuous arm (400 mg; Arm 1) (2-year RFS 100%). ctDNA was only identified in the two subjects with recurrent disease at median of 7.5 months prior to radiological recurrence. Ribociclib is a safe and well-tolerated adjunct to adjuvant ET in early-stage breast cancer. Delayed initiation of ribociclib at 400 mg continuous dosing was feasible, better tolerated and associated with promising outcomes. ctDNA detection preceded clinical evidence of recurrence and may be considered as a surveillance tool in breast cancer.

Year:

2025

Purpose: Antibody–drug conjugates (ADC) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer. However, knowledge of ADC resistance mechanisms and potential impact on the sequential use of ADCs is limited. In this study, we report the incidence and characterization of TOP1 mutations arising in the setting of ADC resistance in metastatic breast cancer. Experimental Design: Patients with metastatic breast cancer treated with ADCs with available posttreatment plasma-based genotyping were included. TOP1 mutation incidence, mutant allele frequency, and functional characterization were assessed, and incidence was compared with that in patients with metastatic breast cancer not receiving ADC treatment and in The Cancer Genome Atlas. Results: Plasma-based genotyping identified distinct TOP1 mutations (S57C, R364H, W401C, and G359E) in 12.9% of patients (4/31) at the time of disease progression on ADC, compared with 0.7% (3/420) in non–ADC-treated patients with metastatic breast cancer and 0.5% in The Cancer Genome Atlas. The appearance of mutations was associated with clinical cross-resistance, as median duration on the first ADC was 455 versus 52 days for the second ADC. The functional characterization of three novel TOP1-mutant proteins demonstrated that all exhibited reduced enzymatic activity, attenuated covalent DNA binding, and resistance to TOP1 inhibitor ADC payloads SN38 and deruxtecan. Conclusions: We describe the recurrent emergence of functionally altered, resistance-associated TOP1 mutations in vivo under selective pressure from ADCs and the potential impact on mediating cross-resistance to sequential ADCs. TOP1 mutation may represent a biomarker of resistance in this setting, and additional work is needed to optimize biomarkers and ADC payload design to improve outcomes for the sequential use of ADCs. See related commentary by Gwin and Hurvitz, p. 1824

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (32)

Carolina Reduzzi

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Andrew A. Davis

Washington University in St. Louis

UNITED STATES
View details

Joyce O'Shaughnessy

Baylor University Medical Center

UNITED STATES
View details

Gerburg Wulf

Harvard University

UNITED STATES
View details

Ron Bose

Washington University School of Medicine

UNITED STATES
View details

Patrick Neven

University Hospitals Leuven

BELGIUM
View details

Sherene Loi

University of Melbourne

AUSTRALIA
View details

Joohyuk Sohn

Yonsei University College of Medicine

SOUTH KOREA
View details

Adam Brufsky

University of Pittsburgh Medical Center

UNITED STATES
View details

Foluso O. Ademuyiwa

-

UNITED STATES
View details

Mateusz Opyrchal

Associate Professor

Indiana University School of Medicine

UNITED STATES
View details

Cynthia X. Ma

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Rupali Sood

Johns Hopkins University

UNITED STATES
View details

Leif Ellisen

Professor and Program Director, Breast Oncology

Massachusetts General Hospital

UNITED STATES
View details

Francois-Clement Bidard

Professor of Medical Oncology

Institut Curie

FRANCE
View details

Nadia Harbeck

-

GERMANY
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Kevin Kalinsky

Emory University

UNITED STATES
View details

Elgene Lim

Clinical Academic/Professor of Medicine

University of New South Wales

AUSTRALIA
View details

Alberto Zambelli

Associate Professor

University of Milano-Bicocca

ITALY
View details

Amir Behdad

-

UNITED STATES
View details

Ferran Fece de la Cruz

Group Leader

Rigshospitalet

DENMARK
View details

Xin Yuan

Principal investigator

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Aiko Nagayama

Keio University School of Medicine

JAPAN
View details

Gad Getz

Broad Institute

UNITED STATES
View details

Sara Hurvitz

Professor, Division Head

Washington University School of Medicine

UNITED STATES
View details

Minetta Liu

Research Collaborator, Professor

Mayo Clinic

UNITED STATES
View details

Virginia Kaklamani

Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Ioannis Sanidas

Principal Investigator

Massachusetts General Hospital

UNITED STATES
View details

Massimo Cristofanilli

Professor of Medicine

Weill Cornell Medicine

UNITED STATES
View details

Peter Kabos

-

UNITED STATES
View details

Ann Partridge

Vice Chair

Dana-Farber Cancer Institute

UNITED STATES
View details